BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36038253)

  • 1. Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma.
    Romano D; García-Gutiérrez L; Aboud N; Duffy DJ; Flaherty KT; Frederick DT; Kolch W; Matallanas D
    Life Sci Alliance; 2022 Oct; 5(10):. PubMed ID: 36038253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of LATS1 with SMAC links the MST2/Hippo pathway with apoptosis in an IAP-dependent manner.
    García-Gutiérrez L; Fallahi E; Aboud N; Quinn N; Matallanas D
    Cell Death Dis; 2022 Aug; 13(8):692. PubMed ID: 35941108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
    Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
    Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
    Jandova J; Wondrak GT
    J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
    Lu H; Liu S; Zhang G; Bin Wu ; Zhu Y; Frederick DT; Hu Y; Zhong W; Randell S; Sadek N; Zhang W; Chen G; Cheng C; Zeng J; Wu LW; Zhang J; Liu X; Xu W; Krepler C; Sproesser K; Xiao M; Miao B; Liu J; Song CD; Liu JY; Karakousis GC; Schuchter LM; Lu Y; Mills G; Cong Y; Chernoff J; Guo J; Boland GM; Sullivan RJ; Wei Z; Field J; Amaravadi RK; Flaherty KT; Herlyn M; Xu X; Guo W
    Nature; 2017 Oct; 550(7674):133-136. PubMed ID: 28953887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.
    Li YY; Wu C; Shah SS; Chen SM; Wangpaichitr M; Kuo MT; Feun LG; Han X; Suarez M; Prince J; Savaraj N
    Mol Oncol; 2017 Dec; 11(12):1806-1825. PubMed ID: 29094484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
    Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
    [No Abstract]   [Full Text] [Related]  

  • 10. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
    Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
    Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
    Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
    Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
    J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
    Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RICTOR/mTORC2 downregulation in BRAF
    Ponzone L; Audrito V; Landi C; Moiso E; Levra Levron C; Ferrua S; Savino A; Vitale N; Gasparrini M; Avalle L; Vantaggiato L; Shaba E; Tassone B; Saoncella S; Orso F; Viavattene D; Marina E; Fiorilla I; Burrone G; Abili Y; Altruda F; Bini L; Deaglio S; Defilippi P; Menga A; Poli V; Porporato PE; Provero P; Raffaelli N; Riganti C; Taverna D; Cavallo F; Calautti E
    Mol Cancer; 2024 May; 23(1):105. PubMed ID: 38755661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
    Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
    J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
    Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS
    Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
    Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
    Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.